Company / Cash & Equivalents
Structure Therapeutics Inc. Cash & Equivalents History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$799.6M
FY2025
5-year range
$26.1M / $799.6M
FY2022-FY2025
Trend
+371.7%
vs FY2024
Sector context
#23 of 207
Health Care
What the data says
Cash & Equivalents changed +372% YoY in FY2025, a notable deviation from the 3-year average annual change of +267%.
Based on SEC 10-K filings.
$800M in FY2025 with a 3-year CAGR of +212.9%. Top quartile in the Health Care sector.
Improved from $130M to $800M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +212.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 207This company $799.6M Sector average $669.5M
▼
+19.4% above sector average
Key checks
Key Insights
- Structure Therapeutics Inc.'s cash & equivalents has grown for 3 consecutive years.
- 3-year CAGR of +212.9%, indicating consistent growth.
- In FY2025, cash & equivalents increased 371.7% year-over-year.
- Ranks #23 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 9.77 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $799.6M | +371.7% |
| FY2024 | $169.5M | +30.6% |
| FY2023 | $129.8M | +397.5% |
| FY2022 | $26.1M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026